KCA
Search
- Page Path
- HOME > Search
Original Article
- Breast cancer
- Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience
- Jiwon Koh, Jinyong Kim, Go-Un Woo, Hanbaek Yi, So Yean Kwon, Jeongmin Seo, Jeong Mo Bae, Jung Ho Kim, Jae Kyung Won, Han Suk Ryu, Yoon Kyung Jeon, Dae-Won Lee, Miso Kim, Tae-Yong Kim, Kyung-Hun Lee, Tae-You Kim, Jee-Soo Lee, Moon-Woo Seong, Sheehyun Kim, Sungyoung Lee, Hongseok Yun, Myung Geun Song, Jaeyong Choi, Jong-Il Kim, Seock-Ah Im
- Cancer Res Treat. 2025;57(2):443-456. Published online August 21, 2024
- DOI: https://doi.org/10.4143/crt.2024.296
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Considering the high disease burden and unique features of Asian patients with breast cancer (BC), it is essential to have a comprehensive view of genetic characteristics in this population. An institutional targeted sequencing platform was developed through the Korea Research-Driven Hospitals project and was incorporated into clinical practice. This study explores the use of targeted next-generation sequencing (NGS) and its outcomes in patients with advanced/metastatic BC in the real world.
Materials and Methods
We reviewed the results of NGS tests administered to BC patients using a customized sequencing platform—FiRST Cancer Panel (FCP)—over 7 years. We systematically described clinical translation of FCP for precise diagnostics, personalized therapeutic strategies, and unraveling disease pathogenesis.
Results
NGS tests were conducted on 548 samples from 522 patients with BC. Ninety-seven point six percentage of tested samples harbored at least one pathogenic alteration. The common alterations included mutations in TP53 (56.2%), PIK3CA (31.2%), GATA3 (13.8%), BRCA2 (10.2%), and amplifications of CCND1 (10.8%), FGF19 (10.0%), and ERBB2 (9.5%). NGS analysis of ERBB2 amplification correlated well with human epidermal growth factor receptor 2 immunohistochemistry and in situ hybridization. RNA panel analyses found potentially actionable and prognostic fusion genes. FCP effectively screened for potentially germline pathogenic/likely pathogenic mutation. Ten point three percent of BC patients received matched therapy guided by NGS, resulting in a significant overall survival advantage (p=0.022), especially for metastatic BCs.
Conclusion
Clinical NGS provided multifaceted benefits, deepening our understanding of the disease, improving diagnostic precision, and paving the way for targeted therapies. The concrete advantages of FCP highlight the importance of multi-gene testing for BC, especially for metastatic conditions. -
Citations
Citations to this article as recorded by
- Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer
Yoonjin Kwak, Tae-Yong Kim, Hye Seung Lee, Soo Kyung Nam, Hyeon Jeong Oh, Do-Youn Oh, Seock-Ah Im
British Journal of Cancer.2026; 134(10): 1429. CrossRef - Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-B
S.-A. Im, K. Park, J. Koh, C. Park, K.H. Jung, J. Lee, H.K. Ahn, A. Lee, S.H. Sim, M.H. Kim, J.H. Kim, J.H. Kim, K.E. Lee, K.H. Park, J. Bae, M.H. Lee, S. Lim, H.J. Kim, D.-W. Lee, J.H. Jeong, K.S. Lee, J. Sohn, K.J. Suh, J.-Y. Kim, Y.J. Cha, J. Moon, C.-
ESMO Open.2025; 10(10): 105804. CrossRef
- Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer
- 4,575 View
- 237 Download
- 1 Web of Science
- 2 Crossref
Special Article
- Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
- Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim
- Cancer Res Treat. 2024;56(3):721-742. Published online November 29, 2023
- DOI: https://doi.org/10.4143/crt.2023.1043
-
Abstract
PDFPubReaderePub
- In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
-
Citations
Citations to this article as recorded by- Long-Term Response Without Immune-Related Adverse Events to Atezolizumab Treatment in TMB-High Thymoma: A Case Report from the KOSMOS-II Study
In Hee Lee, Moonsik Kim, An Na Seo, Soo Jung Lee, Jee Hyun Kim
Journal of Clinical Medicine.2026; 15(3): 958. CrossRef - Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer
Seong-Keun Yoo, Soomin Ahn, Jinha Hwang, Jongwu Kim, Yunjin Go, Minsuk Kwon, Sung Hee Lim, Seung Tae Kim, Kyoung-Mee Kim, Jeeyun Lee
JCO Precision Oncology.2026;[Epub] CrossRef - Real-World Data: Implementation and Outcomes of Next-Generation Sequencing in the MENA Region
Rami Mahfouz, Reine Abou Zeidane, Tasnim Diab, Ali Tarhini, Eman Sbaity, Houry Kazarian, Yomna El Zibaoui, Nour Sabiha Naji, Mounir Barake, Hazem I. Assi
Diagnostics.2025; 15(10): 1183. CrossRef - Exploring PIXE Applications in Oncology: A Comprehensive Review
G. J. Naga Raju
International Journal of Advanced Research in Science, Communication and Technology.2025; : 261. CrossRef
- Long-Term Response Without Immune-Related Adverse Events to Atezolizumab Treatment in TMB-High Thymoma: A Case Report from the KOSMOS-II Study
- 12,684 View
- 417 Download
- 3 Web of Science
- 4 Crossref
Original Article
- Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
- Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song
- Cancer Res Treat. 2019;51(3):1144-1155. Published online November 20, 2018
- DOI: https://doi.org/10.4143/crt.2018.508
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
Materials and Methods
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
Results
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
Conclusion
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials. -
Citations
Citations to this article as recorded by- Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses
Suhyun Hwangbo, Yoojin Choi, Jae Yong Ryu, Julie Decock
PLOS One.2026; 21(5): e0348414. CrossRef - Exploring the potential effects of acute respiratory failure on patients with early-stage bronchopulmonary cancer
Ziwen Lv, Qi Feng, Junhui Gu, Zhuo Gao, Dong Liu
Scientific Reports.2025;[Epub] CrossRef - Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer
Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun
BMC Women's Health.2024;[Epub] CrossRef - Peripheral and tumor‐infiltrating immune cells are correlated with patient outcomes in ovarian cancer
Weiwei Zhang, Yawen Ling, Zhidong Li, Xingchen Peng, Yazhou Ren
Cancer Medicine.2023; 12(8): 10045. CrossRef - Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods
Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park
Clinical and Molecular Hepatology.2022; 28(1): 105. CrossRef - Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
Stanislas Quesada, Michel Fabbro, Jérôme Solassol
Cancers.2022; 14(4): 1098. CrossRef - Construction and validation of a transcription factors-based prognostic signature for ovarian cancer
Qingyuan Cheng, Liman Li, Mingxia Yu
Journal of Ovarian Research.2022;[Epub] CrossRef - Predicting preterm birth through vaginal microbiota, cervical length, and WBC using a machine learning model
Sunwha Park, Jeongsup Moon, Nayeon Kang, Young-Han Kim, Young-Ah You, Eunjin Kwon, AbuZar Ansari, Young Min Hur, Taesung Park, Young Ju Kim
Frontiers in Microbiology.2022;[Epub] CrossRef - Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
Jiayi Li, Dongyan Cao
Frontiers in Oncology.2022;[Epub] CrossRef - Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer
Judan Zeng, Wenjiao Cao, Lihua Wang
Journal of Shanghai Jiaotong University (Science).2021; 26(1): 10. CrossRef - Sphingolipids as multifaceted mediators in ovarian cancer
MelissaR Pitman, Martin K. Oehler, Stuart M. Pitson
Cellular Signalling.2021; 81: 109949. CrossRef - Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition
Jiani Yang, Jun Ma, Yue Jin, Shanshan Cheng, Shan Huang, Nan Zhang, Yu Wang
Scientific Reports.2021;[Epub] CrossRef - Prediction Models for the Clinical Severity of Patients With COVID-19 in Korea: Retrospective Multicenter Cohort Study
Bumjo Oh, Suhyun Hwangbo, Taeyeong Jung, Kyungha Min, Chanhee Lee, Catherine Apio, Hyejin Lee, Seungyeoun Lee, Min Kyong Moon, Shin-Woo Kim, Taesung Park
Journal of Medical Internet Research.2021; 23(4): e25852. CrossRef - Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
Cancers.2021; 13(8): 1875. CrossRef - M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection
Jianwen Hu, Yongchen Ma, Ju Ma, Yanpeng Yang, Yingze Ning, Jing Zhu, Pengyuan Wang, Guowei Chen, Yucun Liu
Frontiers in Oncology.2021;[Epub] CrossRef - Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization
Ji-Bin Liu, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Hui-Min Wang, Yi Shi, Zhi-Zhen Li, Jing-Han Wang, Zhi-Jun Wu, Xiao-Qing Jiang, Gao-Ren Wang, Yu-Shui Ma, Da Fu
Current Problems in Cancer.2020; 44(6): 100612. CrossRef - Can we predict who lives long with ovarian cancer?
Michael A. Bookman
Cancer.2019; 125(S24): 4578. CrossRef
- Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses
- 12,237 View
- 271 Download
- 18 Web of Science
- 17 Crossref
First
Prev
